August 2011 - Sober News

FDA: Regulatory science plan positions agency to foster innovation through better science

The U.S. Food and Drug Administration today released its “Strategic Plan for Regulatory Science,” calling for a sweeping modernization of the science used in developing and evaluating products critical to the nation’s health, economy, and security.

Published Wed, Aug 17 2011 11:48 AM by Food and Drug Administration--Press Releases

The Sexual Recovery Institute Hosts Dr. Patrick Carnes Presentation and Panel Discussion in Los Angeles

LOS ANGELES--(BUSINESS WIRE)--The Sexual Recovery Institute Hosts Dr. Patrick Carnes Presentation and Panel Discussion in Los Angeles Read More...

Published Wed, Aug 17 2011 11:08 AM by Sober.com Headlines Powered By Business Wire

FDA approves Zelboraf and companion diagnostic test for late-stage skin cancer

The U.S. Food and Drug Administration today approved Zelboraf (vemurafenib), a drug to treat patients with late-stage (metastatic) or unresectable (cannot be removed by surgery) melanoma, the most dangerous type of skin cancer.

Published Wed, Aug 17 2011 8:38 AM by Food and Drug Administration--Press Releases

Mayo Clinic/Arizona State University Concussion Summit Focuses on High School Athletes

SCOTTSDALE, Ariz.--(BUSINESS WIRE)--Arizona Concussion Summit Read More...

Published Tue, Aug 16 2011 6:39 PM by Sober.com Headlines Powered By Business Wire

Resource Guide (opens in a new window)

Published Mon, Aug 15 2011 8:00 PM by Behavioral Healthcare Current Articles

FDA seeks comment on proposed guidelines for high-quality clinical studies

The FDA today issued draft guidance to help researchers and manufacturers design better quality clinical studies in support of premarket approval (PMA) applications for medical devices.

Published Mon, Aug 15 2011 10:05 AM by Food and Drug Administration--Press Releases

FDA proposes guidelines that clarify benefit-risk determinations for medical devices

For the first time, the U.S. Food and Drug Administration has provided draft guidance clarifying how benefit-risk determinations are made during premarket review of certain medical devices.

Published Mon, Aug 15 2011 10:00 AM by Food and Drug Administration--Press Releases

Forest Laboratories Sends Open Letter to Shareholders

NEW YORK--(BUSINESS WIRE)--Forest Laboratories, Inc. (NYSE: FRX) (“Forest”) today sent the following open letter to all Forest shareholders in connection with the Company’s Annual Meeting on August 18, 2011. August 15, 2011 Dear Fellow Shareholders, As you know, our Annual Meeting will be held this Thursday, August 18, 2011 at 10:00 am EDT. This year’s meeting marks a critical juncture for the Company’s future. We believe you can enhance the value...

Published Mon, Aug 15 2011 8:44 AM by Sober.com Headlines Powered By Business Wire

FDA, state of Arkansas sign agreement to advance regulatory science

An agreement to establish a virtual Center of Excellence for Regulatory Science was signed today between the U.S. Food and Drug Administration’s National Center for Toxicological Research (NCTR) and the state of Arkansas.

Published Fri, Aug 12 2011 9:48 AM by Food and Drug Administration--Press Releases

Health Net Sponsors Operation Peer Support at the Blinded Veterans Association’s 66th National Convention

RANCHO CORDOVA, Calif.--(BUSINESS WIRE)--Health Net Federal Services and MHN to sponsor Operation Peer Support at the Blinded Veterans Association’s national convention in Las Vegas, August 16-20. Read More...

Published Fri, Aug 12 2011 9:27 AM by Sober.com Headlines Powered By Business Wire

Behavioral health IT: The 'haves' and the 'have nots'

As many providers yearn for IT help, one early adopter says its EHR system is “mission critical"

Published Thu, Aug 11 2011 8:00 PM by Behavioral Healthcare Current Articles

Segal Institute for Clinical Research Recognizes CNS Summit Will Help Shape the Future of CNS Drug Development

MIAMI--(BUSINESS WIRE)--Segal Institute for Clinical Research, a consortium of CNS and women’s health research sites, is preparing to again be actively involved in CNS Summit this coming fall. “CNS Summit is a meeting focused on improving the success of researchers developing new treatments for patients suffering from CNS disorders,” said Bonnie Segal, Vice President at Segal Institute for Clinical Research.” It is an assembly by CNS drug developers...

Published Thu, Aug 11 2011 4:55 PM by Sober.com Headlines Powered By Business Wire

August 2011 - Sober News

Syndication

Recent Posts

Archives